- Home
- GBAB vs SRDX Comparison
GBAB vs SRDX Comparison
Compare GBAB & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBAB
- SRDX
- Stock Information
- Founded
- GBAB 2010
- SRDX 1979
- Country
- GBAB United States
- SRDX United States
- Employees
- GBAB N/A
- SRDX N/A
- Industry
- GBAB Investment Managers
- SRDX Medical/Dental Instruments
- Sector
- GBAB Finance
- SRDX Health Care
- Exchange
- GBAB Nasdaq
- SRDX Nasdaq
- Market Cap
- GBAB 400.4M
- SRDX 402.2M
- IPO Year
- GBAB N/A
- SRDX 1998
- Fundamental
- Price
- GBAB $15.53
- SRDX $27.89
- Analyst Decision
- GBAB
- SRDX Buy
- Analyst Count
- GBAB 0
- SRDX 3
- Target Price
- GBAB N/A
- SRDX $43.00
- AVG Volume (30 Days)
- GBAB 69.4K
- SRDX 89.0K
- Earning Date
- GBAB 01-01-0001
- SRDX 11-05-2025
- Dividend Yield
- GBAB 9.18%
- SRDX N/A
- EPS Growth
- GBAB N/A
- SRDX N/A
- EPS
- GBAB N/A
- SRDX N/A
- Revenue
- GBAB N/A
- SRDX $120,801,000.00
- Revenue This Year
- GBAB N/A
- SRDX N/A
- Revenue Next Year
- GBAB N/A
- SRDX $3.38
- P/E Ratio
- GBAB N/A
- SRDX N/A
- Revenue Growth
- GBAB N/A
- SRDX N/A
- 52 Week Low
- GBAB $14.22
- SRDX $26.00
- 52 Week High
- GBAB $17.44
- SRDX $40.39
- Technical
- Relative Strength Index (RSI)
- GBAB 48.96
- SRDX 36.16
- Support Level
- GBAB $15.58
- SRDX $26.73
- Resistance Level
- GBAB $15.77
- SRDX $27.84
- Average True Range (ATR)
- GBAB 0.18
- SRDX 0.72
- MACD
- GBAB 0.01
- SRDX 0.14
- Stochastic Oscillator
- GBAB 54.24
- SRDX 41.40
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Managed Duration Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.